Analyst Ratings For NASDAQ:DOVA – Dova Pharmaceuticals (NASDAQ:DOVA)
Today, Ladenburg Thalmann initiated coverage on NASDAQ:DOVA – Dova Pharmaceuticals (NASDAQ:DOVA) with a Buy.
Some recent analyst ratings include
- 4/26/2018-Ladenburg Thalmann initiated coverage with a Buy rating.
- 3/23/2018-Evercore ISI initiated coverage with a In rating.
- 9/26/2017-Leerink Swann Upgrade from a “Market Perform ” rating to a ” Outperform” rating.
- 7/24/2017-JPMorgan Chase initiated coverage with a Overweight rating.
- On 8/16/2017 Paul B Manning, Director, bought 25,870 with an average share price of $22.30 per share and the total transaction amounting to $576,901.00.
- On 8/15/2017 Steven M Goldman, Director, bought 20,169 with an average share price of $22.23 per share and the total transaction amounting to $448,356.87.
- On 7/5/2017 Alex Sapir, CEO, bought 20,100 with an average share price of $17.00 per share and the total transaction amounting to $341,700.00.
- On 7/5/2017 Kevin Laliberte, VP, bought 6,200 with an average share price of $17.00 per share and the total transaction amounting to $105,400.00.
- On 7/5/2017 Lee F Md Phd Allen, Insider, bought 3,500 with an average share price of $17.00 per share and the total transaction amounting to $59,500.00.
- On 7/5/2017 Steven M Goldman, Director, bought 72,000 with an average share price of $17.94 per share and the total transaction amounting to $1,291,680.00.
Recent Trading Activity for NASDAQ:DOVA – Dova Pharmaceuticals (NASDAQ:DOVA)
Shares of NASDAQ:DOVA – Dova Pharmaceuticals closed the previous trading session at 25.67 up +1.16 4.73% with 21899 shares trading hands.